These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 17612951)

  • 21. Use of benchmark dose and meta-analysis to determine the most sensitive endpoint for risk assessment for dimethoate.
    Reiss R; Gaylor D
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):55-65. PubMed ID: 16099569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism, variability and risk assessment.
    Dorne JL
    Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose.
    Barnes DG; Daston GP; Evans JS; Jarabek AM; Kavlock RJ; Kimmel CA; Park C; Spitzer HL
    Regul Toxicol Pharmacol; 1995 Apr; 21(2):296-306. PubMed ID: 7644719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interspecies extrapolation in risk analysis.
    Travis CC
    Ann Ist Super Sanita; 1991; 27(4):581-93. PubMed ID: 1820730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
    Davis JA; Gift JS; Zhao QJ
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A probabilistic framework for non-cancer risk assessment.
    Chen JJ; Moon H; Kodell RL
    Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple method for quantitative risk assessment of non-threshold carcinogens based on the dose descriptor T25.
    Sanner T; Dybing E; Willems MI; Kroese ED
    Pharmacol Toxicol; 2001 Jun; 88(6):331-41. PubMed ID: 11453374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment factors--applications in health risk assessment of chemicals.
    Falk-Filipsson A; Hanberg A; Victorin K; Warholm M; Wallén M
    Environ Res; 2007 May; 104(1):108-27. PubMed ID: 17166493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
    Foronda NM; Fowles J; Smith N; Taylor M; Temple W
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods for deriving pesticide aquatic life criteria.
    TenBrook PL; Tjeerdema RS; Hann P; Karkoski J
    Rev Environ Contam Toxicol; 2009; 199():19-109. PubMed ID: 19110939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety assessment of boron by application of new uncertainty factors and their subdivision.
    Hasegawa R; Hirata-Koizumi M; Dourson ML; Parker A; Ono A; Hirose A
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):108-14. PubMed ID: 23137930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calculation of benchmark doses from teratology data.
    Auton TR
    Regul Toxicol Pharmacol; 1994 Apr; 19(2):152-67. PubMed ID: 8041913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?
    Brandon EF; Bulder AS; van Engelen JG; Mahieu CM; Mennes WC; Pronk ME; Rietveld AG; van de Ven BM; Ten Voorde SE; Wolterink G; Slob W; Zeilmaker MJ; Bessems JG
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):182-8. PubMed ID: 23871753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interspecies allometric scaling in pharmacokinetics of drugs].
    Sylvia M
    Acta Pharm Hung; 1998 Nov; 68(6):350-4. PubMed ID: 9987199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing interspecies uncertainty using data from studies of anti-neoplastic agents in animals and humans.
    Price PS; Keenan RE; Swartout JC
    Toxicol Appl Pharmacol; 2008 Nov; 233(1):64-70. PubMed ID: 18514247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.